Abstract. Polyclonal expansion of human regulatory T cells (Tregs) prevents xenogeneic rejection by suppressing effector T cell responses in vitro and in vivo. However, a major limitation to using polyclonally expanded Tregs is that they may cause pan-immunosuppressive effects. The present study was conducted to compare the ability of ex vivo expanded human xenoantigen-stimulated Tregs (Xeno-Treg) and polyclonal Tregs (Poly-Treg) to protect islet xenografts from rejection in NOD-SCID interleukin (IL)-2 receptor (IL2r)γ -/-mice. Human cluster of differentiation (CD)4 + CD25 + CD127 lo Tregs, expanded either by stimulating with porcine peripheral blood mononuclear cells (PBMCs) or anti-CD3/CD28 beads, were characterized by immune cell phenotyping, T cell receptor (TCR) Vβ CDR3 spectratyping and performing suppressive activity assays in vitro. The efficiency of adoptively transferred ex vivo human Tregs was evaluated in vivo using neonatal porcine islet cell clusters (NICC) transplanted into NOD-SCID IL-2rγ -/-mice, which received human PBMCs with or without Xeno-Treg or Poly-Treg. Xeno-Treg, which expressed increased levels of human leukocyte antigen-DR and secreted higher levels of IL-10, demonstrated enhanced suppressive capacity in a pig-human mixed lymphocyte reaction. Spectratypes of TCR Vβ4, Vβ10, Vβ18 and Vβ20 in Xeno-Treg showed restriction and expanded clones at sizes of 205, 441, 332 and 196 respectively, compared to those of Poly-Treg. Reconstitution of mice with human PBMCs and Poly-Treg resulted in NICC xenograft rejection at 63 days. Adoptive transfer with human PBMCs and Xeno-Treg prolonged islet xenograft survival beyond 84 days, with grafts containing intact insulin-secreting cells surrounded by a small number of human CD45
+ cells. This study demonstrated that adoptive transfer of ex vivo expanded human Xeno-Treg may potently prevent islet xenograft rejection in humanized NOD-SCID IL2rγ -/-mice compared with Poly-Treg. These findings suggested that adoptive Treg therapy may be used for immunomodulation in islet xenotransplantation by minimizing systemic immunosuppression.
Introduction
Pancreatic islet transplantation is a potential treatment option for type 1 diabetes mellitus; however, the shortage of human pancreas donors continues to restrict clinical transplantation. The pig represents an alternative source of unlimited organs and tissue, making xenotransplantation a potential strategy for use in humans. However, xenogeneic rejection mediated by T cell responses remains a major limitation to its clinical application (1, 2) . Long-term survival of xenogeneic islets in large animal models has been achieved with immunosuppression (3, 4) ; however, the high dose of immunosuppressive agents required, accompanied by their side effects (5, 6) , limits clinical application. Regulatory T cells (Tregs), are critically important for maintaining tolerance and controlling autoimmunity (7-9), therefore they may represent an alternative and novel strategy for achieving transplant tolerance. Previous studies have indicated that adoptive transfer with ex vivo polyclonally expanded human Tregs prevents islet xenograft rejection by suppressing effector T cell responses (10) , and in vitro polyclonally expanded human Tregs maintain their suppressive function in CD4 + CD25 -effector T cells in a xenogeneic-stimulated mixed lymphocyte reaction (11). These findings indicate a possible strategy for overcoming cellular
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xenoresponses in vitro and in vivo. However, a major limitation to using polyclonally expanded Tregs is that they can cause pan-immunosuppressive effects, leading to opportunistic infections and tumor growth, due to their non-specific suppressive functions. Studies in human and animal models have demonstrated that small numbers of alloantigen-specific Tregs exhibit high efficiency to prevent allograft rejection with fewer side effects (12) (13) (14) . Therefore, antigen-specific Tregs may hold immense promise for human immunotherapy. The present study investigated whether ex vivo expanded human Tregs receiving xenoantigen stimulation are more potent than polyclonally expanded Tregs in protecting against islet xenograft rejection in NOD-SCID interleukin (IL)-2 receptor (IL2r)γ -/-mice. (20-26˚C , relative humidity, 40-70%, free access to sterile feeds and sterile water and 12-h light/dark cycle) in the approved Experimental Animal Center at Sichuan University (Chengdu, China). The mice were used for porcine islet transplantation. The procedures described in this study were conducted according to the guidelines set by the Institute of Laboratory Animals Resources Guide for the Care and Use of Laboratory Animals (Institutional Animal Care and Use Committee Guidebook) (15) .
Materials and methods

Animals
Porcine islet isolation and transplantation. NICC were isolated from the pancreas of 1-3 day old piglets and cultured for 6 days, as previously described (16) . The NICC were pooled and 5,000 clusters (10) were transplanted under the renal capsule of both kidneys of NOD-SCID IL2rγ -/-mice. Flow cytometry. Single-cell suspensions were obtained from mouse spleen or peripheral blood at 4-weeks, 9-weeks and 12-weeks following NICC transplantation and were processed using red blood cell lysis buffer (BioLegend, Inc., San Diego, CA, USA), according to the manufacturer's protocol. Human antigen CD45 (368503; BioLegend, Inc.) was used for the flow cytometric analysis of human leukocyte engraftment in the mouse spleen or peripheral blood cell suspension. Human cells were surface stained with fluorescently labeled antibodies specific for the human antigens CD4 (cat. nos. 317407 and 317425), CD25 (cat. nos. 302605 and 302613), CD127 (cat. no. 351323), CD62L (cat. no. 304821), glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR; cat. no. 371223) and HLA-DR (cat. no. 307617) (all from BioLegend, Inc.), in staining buffer at 4˚C for 30 min in the dark, followed by fixation and permeabilization (Fix/Perm buffer; BioLegend, Inc.). Intracellular staining was conducted with fluorescently labeled anti-forkhead box P3 (Foxp3) (cat. no. 320105) and -cytotoxic T-lymphocyte antigen-4 (CTLA-4; cat. no. 369603) antibodies (both BioLegend, Inc.) for 30 min at room temperature. Flow cytometric data were acquired using an LSRII flow cytometer (BD Biosciences).
IL-10 analyses. Total RNA was extracted from Tregs using the RNeasy Mini kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's protocol, followed by cDNA synthesis using the SuperScript™ III First-Strand Synthesis system (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed on the Bio-Rad CFX Connect Real-Time system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using the Platinum SYBR Green qPCR Supermix-UDG (Thermo Fisher Scientific, Inc.). The reaction was 50˚C for 2 min and 95˚C for 2 min followed by 40 cycles of 95˚C for 15 sec and 65˚C for 35 sec. PCR primers specific for human IL-10 were used: Sense 5'-GCC TAA CAT GCT TCG AGA TC-3' and antisense 5'-GGG TTC AGG TAC CGC TTC TC-3'. Human GAPDH primer (Sense 5'-TGC ACC ACC AAC TGC TTA GC-3' and antisense 5'-GGC ATG GAC TGT GGT CAT GAG-3') was used as an internal reference gene and gene expression was normalized to GAPDH expression levels in each PCR reaction (17) .
IL-10 in the supernatants collected from Xeno-Treg and Poly-Treg stimulation cultures was measured by ELISA, using the IL-10 Human ELISA kit (cat. no. BMS215-2TEN; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol.
TCR Vβ CDR3 spectratyping. CDR3 spectratyping was performed as previously described (18) . Briefly, PCR amplification of expanded human Tregs with xenoantigen stimulation of polyclonal stimulation was performed until a plateau was reached. For the 29 human TCR Vβ families, this required 36 PCR amplification cycles, 29 TCR Vβ primers and a Fam-labeled Cβ reverse primer (18) . All the TCR Vβ family primers were provided by Professor Stephen I. Alexander (Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, NSW, Australia; Table I ). The PCR product (1 µl) from this reaction was mixed with 12 µl Hi-Di™ Formamide and 0.2 µl GeneScan™ 500 TAMRA™ dye Size Standard in a 0.5 ml Genetic Analyzer sample tube (all Thermo Fisher Scientific, Inc.). The sample was denatured by heating at 95˚C for 10 min and then rapidly cooled on ice. The sample was then electrophoresed on the ABI Prism ® 310 Genetic Analyzer (Thermo Fisher Scientific, Inc.). An electropherogram of the GeneScan-500 Size Standard was generated under denaturing conditions on the ABI Prism ® 310 Genetic Analyzer. Fragments were run using the POP-4™ Polymer (Thermo Fisher Scientific, Inc.) at 60˚C. When the size of the PCR product was <500 bp, a capillary with dimensions of 47 cm x 50 µm i.d. (Thermo Fisher Scientific, Inc.) was used. If the signal was too strong, the sample injection time or voltage was decreased; or the sample was further diluted. The data were sized and quantified using ABI Prism 310 Genetic Analyzer with built in software (ABI Prism 310 collection; Thermo Fisher Scientific, Inc.).
In vitro Treg suppression assay. The suppressive capacity of Tregs was assessed by measuring inhibition of proliferation in mixed leukocyte reaction (MLR) assays. Proliferation was evaluated using the CellTrace™ Carboxyfluorescein succinimidyl ester (CFSE) Cell Proliferation kit (Invitrogen; Thermo Fisher Scientific, Inc.). Responder cells (human PBMCs) were labeled with 0.5 µM CFSE (Molecular Probes; Thermo Fisher Scientific, Inc.) prior to stimulation. CFSE-labeled responder cells (1x10 5 ) from autologous Treg donors were stimulated with 2x10 5 irradiated xenogeneic stimulator PBMCs or purified anti-human CD3 antibody (BD Biosciences). Tregs were titrated into the cultures at different ratios. After 7 days of culture, the proliferation of responder cells was analyzed by flow cytometry (LSR II; BD Biosciences). AACAGTTCCCTGACTTGCACTCT  BV10  TTCTTCTATGTGGCCCTTTGTCT  BV11  GGCTCAAAGGAGTAGACTCCACTCT  BV12  GGTGACAGAGATGGGACAAGAAGT  BV13  CATCTGATCAAAGAAAAGAGGGA  AAC  BV14  AGAGTCTAAACAGGATGAGTCCGG  TAT  BV15  AGAGTCTAAACAGGATGAGTCCGG  TAT  BV16  AAACAGGTATGCCCAAGGAAAGA  BV18  CAGCCCAATGAAAGGACACAGT  BV19  GGGCAAGGGCTGAGATTGAT  BV20  AACCATGCAAGCCTGACCTT  BV23  TGTACCCCCGAAAAAGGACATAC  BV24  CAGTGTCTCTCGACAGGCACA  BV25  CTCAAACCATGGGCCATGA  BV27  CCAGAACCCAAGATACCTCATCAC  BV28  GGCTACGGCTGATCTATTTCTCA  BV29  GACGATCCAGTGTCAAGTCGATAG  BV30  CTGAGGTGCCCCAGAATCTCT  BC as described previously (10) . Porcine endocrine cells were detected using anti-porcine insulin antibody (IR00261-2 insulin; 1:100; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) and the VECTASTAIN ® ABC kit (Vector Laboratories, Inc., Burlingame, CA, USA). Graft-infiltrating human leukocytes were stained using anti-human CD45 antibody (14-9457-82; 1:200; eBioscience; Thermo Fisher Scientific, Inc.), followed by incubation with horseradish peroxidase-conjugated secondary rabbit anti-mouse antibody (31451; 1:200, Thermo Fisher Scientific, Inc.), then analyze using a Zeiss microscope (AX10; Zeiss AG, Oberkochen, Germany).
Statistical analysis.
Results comparisons involving two groups were analyzed using Student's t-test (two-tailed) and those involving multiple groups were analyzed using one-way analysis of variance with the Tukey multiple comparison test by SPSS version 22 (IBM Corp., Armonk, NY, USA). Graft survival was evaluated using Kaplan-Meier analysis. The data were presented as the means ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.
Results
Human Tregs expanded ex vivo with xenoantigen stimulation retain Treg phenotype and secrete IL-10.
The phenotype of Xeno-Treg was examined by flow cytometry. After two cycles of xenoantigen stimulation, Xeno-Treg retained the classic Treg phenotype, as did Poly-Treg, which is characterized by high levels of CD25, Foxp3, CTLA-4, CD62L and GITR expression, and very low or undetectable CD127 expression (Fig. 1) . However, compared with Poly-Treg, Xeno-Treg expressed more HLA-DR, which has been described as an effector marker of Treg (20, 21) (Fig. 1) .
IL-10 expression in Tregs was assessed by RT-qPCR. Xenoantigen stimulation led to an upregulation of IL-10 expression, with expression levels 7-fold higher compared with Poly-Treg ( Fig. 2A; P<0.01 ). In addition, IL-10 secretion was measured in the cell culture supernatants of Tregs receiving xenoantigen or polyclonal stimulation. Consistent with mRNA expression, IL-10 secretion by Xeno-Treg was enhanced compared with Poly-Treg (Xeno-Treg: 175±18.9 pg/ml vs. Poly-Treg: 86±16.4 pg/ml; Fig. 2B ; P<0.01). These results demonstrated that Xeno-Treg may retain a Treg phenotype, but secrete higher levels of IL-10 compared with Poly-Treg, which may result in greater suppressive potency.
Tregs exhibit restricted TCR Vβ repertoire following xenoantigen stimulation.
Spectratyping was used to analyze the TCR Vβ families at the CDR3 level and screen for clonal expansion of specific T cells (22) (23) (24) . All 29 TCR Vβ families were detected in Xeno-Treg or Poly-Treg, and in control CD4 + T cells. However, there were altered TCR Vβ repertoires in both Xeno-Treg and Poly-Treg compared with in CD4 + T cells. Increased expression of TCR Vβ4, Vβ7-9, Vβ20, Vβ28 (>5% in repertoire) and TCR Vβ10 and Vβ18 were observed in Xeno-Treg and Poly-Treg compared with in CD4 + T cells (Fig. 3) . In addition, expression levels of TCR Vβ4, Vβ10, Vβ18 and Vβ20 were markedly increased in Xeno-Treg compared with in Poly-Treg (Fig. 3) .
Overall spectratyping of PCR products revealed a restricted TCR Vβ repertoire in Xeno-Treg and Poly-Treg compared with in CD4 + T cells, which possessed a diverse TCR Vβ repertoire. Nearly all the TCR Vβ families exhibited a Gaussian distribution, with the exception of TCR Vβ3, Vβ7-7, Vβ19 and Vβ23 (Fig. 4) 55 and 45% suppression of responder cell proliferation at low responder cell: Treg ratios of 1:1/8 and 1:1/16, respectively (Fig. 7A ). Even at a higher responder cell: Treg ratio of 1:1/32, Xeno-Treg still demonstrated >35% suppression of responder cell proliferation, which was 2.5-fold higher compared with Poly-Treg (Fig. 7A) . These data revealed that Xeno-Treg possess enhanced and xenoantigen-specific suppressive capacity. However, both Xeno-and Poly-Treg demonstrated similar ability to suppress responder cell proliferation in a polyclonally-stimulated MLR (Poly MLR) assay (Fig. 7B) , thus suggesting that xenoantigen stimulation did not alter the capacity to suppress polyclonally-stimulated responses.
Human Treg expanded ex vivo with xenoantigen stimulation prevent rejection of porcine islet xenografts. To determine the in vivo suppressive capacity of ex vivo expanded Xeno-Treg, a total of 1x10 7 CD25 + cell-depleted PBMCs with or without 1x10 6 autologous ex vivo expanded Xeno-Treg or Poly-Treg were injected intravenously into NOD-SCID IL2rγ -/-mice 3 days after NICC transplantation. Nonreconstituted mice were used as a control. Mice that were reconstituted with human PBMCs, rejected their xenografts completely within 28 days of transplantation, whereas NICC grafts survived for ≥84 days in nonreconstituted recipients (Fig. 8A) . In mice reconstituted with Xeno-Treg and PBMCs (Xeno-Treg:PBMC ratio of 1:10), 75% of NICC xenografts survived beyond 84 days (Fig. 8A) . In contrast, in mice reconstituted with Poly-Treg and PBMCs (Poly-Treg:PBMC ratio of 1:10), 75% of NICC xenografts survived ≥48 days, 25% of NICC xenografts survived until day 56, and all xenografts were rejected by day 63 (Fig. 8A) . These results suggested that Xeno-Treg may prolong NICC xenograft survival.
Human leukocyte engraftment was confirmed by flow cytometry. Following human Poly-Treg and PBMC adoptive transfer, the spleen and peripheral blood was engrafted with 27.3±6.3 and 14.7±4.2% of human CD45 + cells respectively, by day 63 (Fig. 8B) . However, following human Xeno-Treg and PBMC adoptive transfer, the spleen and peripheral blood was engrafted with 15.2±3.8 and 10.5±3.2% of human CD45 + cells respectively, by day 84 (Fig. 8B) . Decreased engraftment of human CD45
+ cells in mice reconstituted with Xeno-Treg and PBMCs may indicate that graft survival is as a result of xenoantigen-specific Treg-mediated suppression and not due to engraftment failure.
Immunohistochemistry of NICC grafts from nonreconstituted recipients revealed intact insulin-positive cells with no CD45 + cells infiltration (Fig. 9A-C) . Numerous graft-infiltrating human CD45 + cells were detected in the rejected xenografts from PBMC-reconstituted mice; however, no insulin-positive cells were visible (Fig. 9D-F) . Long-term surviving grafts from Xeno-Treg-and PBMC-reconstituted mice contained intact insulin-secreting cells surrounded by a small number of human CD45 + cells (Fig. 9G-I ). On day 63, immunohistochemistry of NICC grafts from Poly-Treg-and PBMC-reconstituted mice revealed small, damaged and insulin-positive cells with numerous graft-infiltrating human CD45 + cells (Fig. 9J-L) . These results suggested that adoptive transfer of ex vivo expanded Xeno-Treg may possess a greater capacity to reduce xenograft damage and prevent rejection of porcine islet xenografts compared with Poly-Treg.
Discussion
The use of efficient antigen-specific Tregs may reduce the number of Tregs required for therapy and lower the risk of systemic immunosuppression (25, 26) . Numerous studies have investigated strategies for large-scale expansion of alloantigen-specific human Tregs (27) (28) (29) , and ex vivo alloantigen-specific Tregs were shown to possess enhanced suppressive capacity in allogeneic responses in vitro and in vivo (30, 31) . In the present study, a strategy using one cycle of polyclonal stimulation followed by two subsequent cycles of xenoantigen stimulation was developed to selectively expand Xeno-Treg. Following stimulation, spectratyping was conducted to analyze the TCR Vβ families of Tregs at the CDR3 level and screen for clonal expansion of specific T cells. CDR3 spectratyping is a well-described method for measuring oligoclonality within T cell populations (32) . Normal PBMC samples of a single Vβ family display a Gaussian distribution of 6-11 peaks, each separated by three nucleotides. Each peak corresponds to a TCR transcript with a given CDR3 length that may contain numerous sequences (32) . The number of TCR transcripts with a specific CDR3 length is proportional to the area under each peak. An increase in the height and area of a size peak typically indicates oligoclonal or monoclonal expansion in the polyclonal T cell background. Oligoclonal T cells give fewer peaks in a restricted distribution. Single clones give a single peak. This method has been used previously to screen PCR products in an efficient manner for possible T cell clonal expansion following MLR, renal biopsies and urine at the time of rejection (22,33). The present study identified an increase in the expression of TCR Vβ4, TCR Vβ10, TCR Vβ18 and TCR Vβ20 families for Xeno-Treg compared with Poly-Treg. In addition, spectratypes of TCR Vβ4, Vβ10, Vβ18 and Vβ20 in Xeno-Treg demonstrated restriction and expanded clone at size 205, 441, 332 and 196, respectively, which indicated that Treg acquired xenoantigen specificity following xenoantigen stimulation by identifying the specific expanded clones in TCR Vβ families. Furthermore, Xeno-Treg were acquired and showed enhanced suppressive capacity in the xenoimmune response detected in a MLR.
The mechanisms underlying human xenoantigen-specific Treg suppressive functions in vivo remain largely unknown. Previous studies have revealed that IL-10 serves a critical role in Treg-mediated suppression of xenogeneic responses in vivo and in vitro (10, 34, 35) . In the present study, Xeno-Treg upregulated the expression of IL-10 and produced more IL-10, compared with Poly-Treg, in the culture medium. Therefore, it may be hypothesized that the suppressive functions of Xeno-Treg in the Xeno MLR assay are mediated by IL-10. Furthermore, the results demonstrated that Xeno-Treg expressed increased levels of HLA-DR, thus suggesting that IL-10 secretion of Xeno-Treg was associated with the upregulated effector marker. Yi et al demonstrated that adoptive transfer with expanded autologous Tregs prevents islet xenograft rejection in human PBMC-reconstituted mice, by inhibiting graft infiltration of effector cells and their function via IL-10 (10). In the present study, NOD-SCID IL2rγ -/-mice reconstituted with Xeno-Treg and PBMCs at a Xeno-Treg:PBMC ratio of 1:10; 75% of NICC xenografts contained intact insulin-secreting cells, which survived beyond 84 days compared with the Poly-Treg-and PBMC-reconstituted group, in which 75% of NICC xenografts survived to day 48 and by day 63 all xenografts showed small, damaged and insulin positive-staining cells, with a large number of graft-infiltrating human CD45 + cells. These findings suggested that adoptively transferred ex vivo expanded Xeno-Treg may display a greater capacity to reduce xenograft damage and prevent porcine islet xenograft rejection compared with Poly-Treg. However, the mechanisms of human xenoantigen-specific Treg suppressive function in vivo remain largely unknown. Further studies are required to explore whether IL-10 has an important role in human xenoantigen-specific Treg suppressive function in vivo.
In conclusion, the present study demonstrated that adoptive transfer with ex vivo expanded Xeno-Treg exhibited a greater capacity to prevent islet xenograft rejection in humanized NOD-SCID IL2rγ -/-mice compared with Poly-Treg, thus suggesting a novel strategy for adoptive Treg cell therapy for immunomodulation in islet xenotransplantation that may minimize systemic immunosuppression.
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